Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies [Phase 1]
Phase 1 study evaluating safety and tolerability of immunotherapy combinations in triple-negative breast cancer and ovarian cancer has compl…
-
CLINICAL_TRIALS trial_result · 2024-05-21Clinical Trial Update: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients [Phase 2]
Phase 2 neoadjuvant trial in triple-negative breast cancer evaluating dose-dense EC followed by ABX plus a PD-1 inhibitor; the study is curr…
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer [Phase 1, Phase 2]
Clinical trial update reporting results for neoadjuvant nivolumab in combination with chemotherapy for localized triple-negative breast canc…
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) [Phase 1]
Exelixis reports that the QUARTZ-101 Phase 1 trial of XL102 as a single agent and in combination therapy for solid tumors has been terminate…
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1 and Phase 2 trials evaluated tinengotinib (TT-00420) as a monotherapy and in combination therapy for patients with advanced solid tu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-16Clinical Trial Update: A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer [Phase 3]
Phase 3 trial investigating camrelizumab plus chemotherapy versus chemotherapy alone for metastatic triple-negative breast cancer; study ter…
-
CLINICAL_TRIALS trial_result · 2024-04-15Clinical Trial Update: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors [Phase 2]
Phase 2 trial evaluating safety and efficacy of TJ107 combined with PD-1 in patients with solid tumors, including triple-negative breast can…
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer [Phase 2]
A Phase II neoadjuvant trial combining pembrolizumab with carboplatin and docetaxel in triple-negative breast cancer is ongoing with active …
-
CLINICAL_TRIALS trial_result · 2024-04-08Clinical Trial Update: Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo [Phase 3]
Phase 3 trial updating neoadjuvant chemotherapy with atezolizumab or placebo in triple-negative breast cancer, followed by atezolizumab or p…
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating ipatasertib with atezolizumab and paclitaxel in locally advanced or metastatic triple-negative breast cancer has co…
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) [Phase 3]
A Phase 3 trial comparing camrelizumab plus chemotherapy versus placebo plus chemotherapy as neoadjuvant therapy in triple negative breast c…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy [Phase 3]
Phase 3 clinical trial evaluating capecitabine plus camrelizumab for non-pCR triple-negative breast cancer with tumor-infiltrating lymphocyt…
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating GX-I7 in combination with pembrolizumab for refractory or relapsed triple negative breast cancer has c…
-
CLINICAL_TRIALS trial_result · 2024-03-01Clinical Trial Update: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma [Phase 2]
This Phase 2 trial evaluating NIR178 in combination with PDR001 across multiple solid tumors and non-Hodgkin lymphoma was terminated, with r…
-
CLINICAL_TRIALS trial_result · 2024-03-01Clinical Trial Update: Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer [Phase 2]
Phase 2 trial evaluating bevacizumab, carboplatin, gemcitabine, and atezolizumab in metastatic triple-negative breast cancer; status is curr…
-
CLINICAL_TRIALS trial_result · 2024-02-26Clinical Trial Update: First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients [Phase 2]
Phase 2 trial update on first-line nab-paclitaxel, cisplatin, and carilizumab in metastatic triple-negative breast cancer (mTNBC).
-
CLINICAL_TRIALS trial_result · 2024-02-23Clinical Trial Update: Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer [Phase 2]
This ClinicalTrials.gov update reports completion of a Phase 2 trial evaluating autologous tumor-infiltrating lymphocytes in patients with p…
-
CLINICAL_TRIALS trial_result · 2024-02-22Clinical Trial Update: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial update reporting results for pamiparib (BGB-290) in adults with advanced solid tumors, including advanced high-grad…
-
CLINICAL_TRIALS trial_result · 2024-02-22Clinical Trial Update: Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer [Phase 1, Phase 2]
Phase 1/2 trial of pembrolizumab added to standard-of-care chemotherapy for triple-negative breast cancer has posted results; the study rema…
-
CLINICAL_TRIALS trial_result · 2024-02-21Clinical Trial Update: A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) [Phase 3]
Phase 3 trial investigating camrelizumab plus chemotherapy with or without famitinib as neoadjuvant therapy for triple-negative breast cance…
-
CLINICAL_TRIALS trial_result · 2024-02-16Clinical Trial Update: Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial update reporting results of Abraxane with or without mifepristone in advanced glucocorticoid receptor-positive triple-negative…
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) [Phase 2]
Phase 2 trial comparing olaparib plus pembrolizumab to chemotherapy plus pembrolizumab after induction with first-line chemotherapy in tripl…
-
CLINICAL_TRIALS trial_result · 2024-02-12Clinical Trial Update: A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer [Phase 2]
Phase 2 trial of AL101 monotherapy in notch-activated triple-negative breast cancer has been terminated; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-02-12Clinical Trial Update: Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease [Phase 2]
Phase 2 trial evaluating radiotherapy with nivolumab and ipilimumab vs radiotherapy with capecitabine for residual disease in triple-negativ…
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. [Phase 3]
Phase 3 trial evaluating famitinib in combination with camrelizumab and TPC as first-line treatment for immunomodulatory locally advanced or…